Tagged with

Mexico Rogerio Peso outlines how Viatris leverages collaborations to address critical healthcare needs in Mexico, combining its strengths with other stakeholders to improve patient outcomes. With a mission to offer high-quality, affordable medicines, Peso also points out how Viatris aligns its portfolio with the healthcare needs of Latin America, addressing gaps…

Global Aitia Bio’s Colin Hill, writing in the November 2024 issue of DIA’s Global Forum magazine outlines why “digital twins” – virtual models of patients, systems, or devices that simulate real-world data to predict outcomes, optimize treatments, and improve patient care – have the potential to reshape the entire drug development…

Singapore Writing in the November 2024 edition of DIA’s Global Forum magazine, Johnson & Johnson’s Sandy Chan looks at the fast-evolving regulatory framework for medicines in the dynamic Asia-Pacific region.   Asia Pacific (AP) is an immensely diverse and dynamic region with varying regulatory capabilities and capacities; consequently, AP regulators and…

UK Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional cash to R&D, and incentivise manufacturing through a new GBP 520 million Life Sciences Innovative Manufacturing Fund (LSIMF).   Addressing…

Mexico With the naming of Armida Zuñiga as head of the country’s regulatory body COFEPRIS, new Mexican president Claudia Sheinbaum has concluded the new government’s healthcare appointments and begun advancing her agenda by tackling Mexico’s widespread medicine shortages.   New Regulatory Lead By the time Claudia Sheinbaum was sworn in as…

China An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue decline, and Aditum Bio and Leads Biolabs’ creation of autoimmune disease-focused Oblenio Bio. AstraZeneca’s China chief in custody, believes unrelated…

Switzerland Michael Kubischik shares his career journey and Sanofi’s strategic focus in Switzerland. He highlights Sanofi’s dedication to become the world´s leading immunology company, supported by initiatives like AI integration and efficient regulatory processes to improve patient access, as well as the benefits of working for a company with such a…

Mexico Emily Morris, head of Sanofi in Latin America discusses the company’s transformative journey under the 2019-initated ‘Play to Win’ strategy. With an emphasis on optimizing their portfolio and prioritizing immunoscience, she highlights Sanofi’s commitment to leveraging AI to enhance patient access to innovative therapies. Morris also delves into the importance…

Mexico Monica Palomanes, General Manager of Roche Mexico, discusses her journey within the company and the shift from traditional sales to a collaborative approach with Patient Journey Partners. She addresses challenges in access and diagnosis within Mexico’s fragmented healthcare system, while recognising the country’s potential for clinical research due to the…

Switzerland Georg Pirmin Meyer, SVP and Head of International at Blueprint Medicines, shares insights into the company’s journey from a promising startup to a fast-scaling biotech leader focused on allergy/inflammation and haematology/oncology. Meyer discusses Blueprint’s innovative approach to international expansion, patient-centric strategy, and ambitious plans for growth in new markets. He…

Puerto Rico Yandia Perez is the executive vice president of the Puerto Rico Manufacturers Association (PRMA), an organization celebrating its 95th anniversary and dedicated to fostering a strong manufacturing ecosystem on the island. Under her leadership, PRMA has prioritized not only the pharmaceutical sector, which constitutes about 30% of Puerto Rico’s GDP,…

Global Traditional drug discovery is fraught with failure and often like trying to find a needle in a haystack. Even once a candidate is identified, the development process takes thousands of man-hours and generally billions of dollars. Artificial Intelligence has the potential to change this paradigm. It can aggregate and synthesize…